InflaRx (IFRX)
(Delayed Data from NSDQ)
$1.45 USD
+0.01 (0.69%)
Updated Sep 18, 2024 04:00 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
IFRX 1.45 +0.01(0.69%)
Will IFRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IFRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IFRX
InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
IFRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing
After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)
InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for IFRX
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
InflaRx presents new preclinical findings for INF904
InflaRx Announces Participation in September Investor Events
InflaRx Buy Rating Backed by Promising Drug Prospects and Financial Stability
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Krystal Biotech (KRYS) and InflaRx (IFRX)